TRML: Tourmaline Bio, Inc. - Summary | Jitta

Tourmaline Bio, Inc.

NASDAQ:TRML

Notice
Stock data is unavailable or the company’s delisted.
Price
$47.98
Loss Chance
59.6%
n/aJITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (0)
Recent Business Performance (17)
Financial Strength (37)
Return to Shareholders (0)
Competitive Advantage (1)
Jitta Signs
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Recent Business PerformanceEarning decline 31.16% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
n/a
100.00%
2.24
319.59%
2.24
319.59%
COMPANY DESCRIPTION
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. The company develops pacibekitug, a long-acting, fully human, anti-IL-6 antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity and high binding affinity to IL-6. It develops medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was incorporated in 2002 and is based in New York, New York. As of September 9, 2025, Tourmaline Bio, Inc. operates as a subsidiary of Novartis AG.